Literature DB >> 33049112

Laboratory variability in the diagnosis of type 2 VWD variants.

Stefanie DiGiandomenico1, Pamela A Christopherson2, Sandra L Haberichter1,2, Thomas C Abshire1,2, Robert R Montgomery1,2, Veronica H Flood1,2,3.   

Abstract

Essentials Patients with von Willebrand disease were enrolled in our study. Type 2 VWD diagnoses were based on original test results. Repeat evaluation resulted in many patients receiving a different type 2 diagnosis. Some genetic variants were particularly likely to move type 2 subcategories. ABSTRACT: Introduction Type 2 von Willebrand disease (VWD) refers to patients with a qualitative defect in von Willebrand factor. Accurate diagnosis of type 2 VWD subtypes can be challenging. Aim of the study To compare the historical diagnosis of type 2 VWD with current laboratory testing. Methods Subjects were enrolled in the Zimmerman Program either because of a preexisting diagnosis of VWD (retrospective cohort) or from evaluation for bleeding symptoms or suspected VWD (prospective cohort). Original diagnosis was assigned by the local center and central diagnosis was based on central laboratory testing. Results Two hundred and seventeen index cases in the retrospective cohort and 35 subjects in the prospective cohort carried a local diagnosis of type 2 VWD (29% and 6% of enrolled index cases, respectively). In the retrospective cohort, the diagnosis was confirmed in 66% of cases with a preexisting diagnosis of 2A, 77% 2B, 54% 2M, and 72% 2N. In the prospective cohort, 31% were confirmed 2A, 60% 2B, 23% 2M, and 100% 2N. Several genetic variants were repeatedly implicated in subjects with changed diagnosis: p.M1304R, p.R1315C, p.R1374C, and p.R1374H. Conclusions Both the prospective and retrospective cohorts demonstrated consistent variation in subjects whose diagnosis changed between 2A, 2B, and 2M. The importance of accurately diagnosing type 2 VWD may be most significant in the 2B subtype given potential concerns with the use of desmopressin in type 2B VWD. Some genetic variants appear in multiple types of VWD, making specific diagnoses challenging.
© 2020 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  Von Willebrand disease; Von Willebrand factor; genetic; medical laboratory science; polymorphism; ristocetin

Mesh:

Substances:

Year:  2020        PMID: 33049112      PMCID: PMC7790985          DOI: 10.1111/jth.15129

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  27 in total

Review 1.  Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.

Authors:  Giancarlo Castaman; Augusto B Federici; Francesco Rodeghiero; Pier Mannuccio Mannucci
Journal:  Haematologica       Date:  2003-01       Impact factor: 9.941

Review 2.  Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH.

Authors:  I Bodó; J Eikenboom; R Montgomery; J Patzke; R Schneppenheim; J Di Paola
Journal:  J Thromb Haemost       Date:  2015-05-09       Impact factor: 5.824

Review 3.  Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.

Authors:  J E Sadler; U Budde; J C J Eikenboom; E J Favaloro; F G H Hill; L Holmberg; J Ingerslev; C A Lee; D Lillicrap; P M Mannucci; C Mazurier; D Meyer; W L Nichols; M Nishino; I R Peake; F Rodeghiero; R Schneppenheim; Z M Ruggeri; A Srivastava; R R Montgomery; A B Federici
Journal:  J Thromb Haemost       Date:  2006-08-02       Impact factor: 5.824

4.  Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor.

Authors:  Veronica H Flood; Joan Cox Gill; Patricia A Morateck; Pamela A Christopherson; Kenneth D Friedman; Sandra L Haberichter; Brian R Branchford; Raymond G Hoffmann; Thomas C Abshire; Jorge A Di Paola; W Keith Hoots; Cindy Leissinger; Jeanne M Lusher; Margaret V Ragni; Amy D Shapiro; Robert R Montgomery
Journal:  Blood       Date:  2010-03-15       Impact factor: 22.113

5.  Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD.

Authors:  Veronica H Flood; Joan Cox Gill; Patricia A Morateck; Pamela A Christopherson; Kenneth D Friedman; Sandra L Haberichter; Raymond G Hoffmann; Robert R Montgomery
Journal:  Blood       Date:  2010-12-10       Impact factor: 22.113

6.  Clinical and laboratory phenotype variability in type 2M von Willebrand disease.

Authors:  A L Doruelo; S L Haberichter; P A Christopherson; L N Boggio; S Gupta; S R Lentz; A D Shapiro; R R Montgomery; V H Flood
Journal:  J Thromb Haemost       Date:  2017-06-23       Impact factor: 5.824

7.  Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in Type IIB von Willebrand's disease.

Authors:  L Holmberg; I M Nilsson; L Borge; M Gunnarsson; E Sjörin
Journal:  N Engl J Med       Date:  1983-10-06       Impact factor: 91.245

8.  Abnormal binding of factor VIII is linked with the substitution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand disease.

Authors:  P A Kroner; K D Friedman; S A Fahs; J P Scott; R R Montgomery
Journal:  J Biol Chem       Date:  1991-10-15       Impact factor: 5.157

9.  Towards improved diagnosis of von Willebrand disease: comparative evaluations of several automated von Willebrand factor antigen and activity assays.

Authors:  Emmanuel J Favaloro; Soma Mohammed
Journal:  Thromb Res       Date:  2014-09-28       Impact factor: 3.944

10.  The rapid differentiation of type IIb von Willebrand's disease from platelet-type (pseudo-) von Willebrand's disease by the "neutral" monoclonal antibody binding assay.

Authors:  J P Scott; R R Montgomery
Journal:  Am J Clin Pathol       Date:  1991-12       Impact factor: 2.493

View more
  5 in total

Review 1.  Von Willebrand Disease: Current Status of Diagnosis and Management.

Authors:  Angela C Weyand; Veronica H Flood
Journal:  Hematol Oncol Clin North Am       Date:  2021-08-13       Impact factor: 3.722

2.  Von Willebrand disease type 2M: Correlation between genotype and phenotype.

Authors:  Dominique P M S M Maas; Ferdows Atiq; Nicole M A Blijlevens; Paul P T Brons; Sandy Krouwel; Britta A P Laros-van Gorkom; Frank W G Leebeek; Laurens Nieuwenhuizen; Selene C M Schoormans; Annet Simons; Daniëlle Meijer; Waander L van Heerde; Saskia E M Schols
Journal:  J Thromb Haemost       Date:  2021-11-21       Impact factor: 16.036

3.  Phenotypic and genetic characterizations of the Milan cohort of von Willebrand disease type 2.

Authors:  Omid Seidizadeh; Luciano Baronciani; Maria Teresa Pagliari; Giovanna Cozzi; Paola Colpani; Andrea Cairo; Simona Maria Siboni; Eugenia Biguzzi; Flora Peyvandi
Journal:  Blood Adv       Date:  2022-07-12

4.  2B von Willebrand disease diagnosis: Considerations reflecting on 2021 multisociety guidelines.

Authors:  Maha Othman; Emmanuel J Favaloro
Journal:  Res Pract Thromb Haemost       Date:  2021-12-20

5.  Resolving Differential Diagnostic Problems in von Willebrand Disease, in Fibrinogen Disorders, in Prekallikrein Deficiency and in Hereditary Hemorrhagic Telangiectasia by Next-Generation Sequencing.

Authors:  Réka Gindele; Adrienne Kerényi; Judit Kállai; György Pfliegler; Ágota Schlammadinger; István Szegedi; Tamás Major; Zsuzsanna Szabó; Zsuzsa Bagoly; Csongor Kiss; János Kappelmayer; Zsuzsanna Bereczky
Journal:  Life (Basel)       Date:  2021-03-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.